Victory Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $35.9M | Buy |
122,126
+103,487
| +555% | +$29.4M | 0.02% | 713 |
|
|
2026
Q1 | $5.2M | Buy |
18,639
+4,761
| +34% | +$1.37M | ﹤0.01% | 1314 |
|
|
2025
Q4 | $4.2M | Buy |
13,878
+11,149
| +409% | +$3.48M | ﹤0.01% | 1374 |
|
|
2025
Q3 | $765K | Sell |
2,729
-27,753
| -91% | -$7.55M | ﹤0.01% | 1959 |
|
|
2025
Q2 | $7.36M | Buy |
30,482
+740
| +2% | +$175K | ﹤0.01% | 1200 |
|
|
2025
Q1 | $7.24M | Buy |
29,742
+7,525
| +34% | +$2.26M | 0.01% | 1166 |
|
|
2024
Q4 | $7.3M | Buy |
22,217
+923
| +4% | +$313K | 0.01% | 1168 |
|
|
2024
Q3 | $7.12M | Buy |
21,294
+186
| +0.9% | +$59.1K | 0.01% | 1196 |
|
|
2024
Q2 | $5.76M | Buy |
21,108
+3,298
| +19% | +$959K | 0.01% | 1225 |
|
|
2024
Q1 | $6.16M | Buy |
17,810
+139
| +0.8% | +$45.7K | 0.01% | 1194 |
|
|
2023
Q4 | $5.71M | Buy |
17,671
+5,790
| +49% | +$1.81M | 0.01% | 1211 |
|
|
2023
Q3 | $4.26M | Sell |
11,881
-895
| -7% | -$345K | ﹤0.01% | 1236 |
|
|
2023
Q2 | $4.84M | Buy |
12,776
+6,273
| +96% | +$2.55M | 0.01% | 1211 |
|
|
2023
Q1 | $3.12M | Sell |
6,503
-4,162
| -39% | -$1.95M | ﹤0.01% | 1298 |
|
|
2022
Q4 | $4.48M | Buy |
10,665
+2,795
| +36% | +$1.13M | 0.01% | 1224 |
|
|
2022
Q3 | $3.28M | Sell |
7,870
-4,438
| -36% | -$2.21M | ﹤0.01% | 1342 |
|
|
2022
Q2 | $6.09M | Sell |
12,308
-470
| -4% | -$245K | 0.01% | 1204 |
|
|
2022
Q1 | $6.56M | Sell |
12,778
-201
| -2% | -$121K | 0.01% | 1242 |
|
|
2021
Q4 | $9.81M | Buy |
12,979
+12
| +0.1% | +$8.98K | 0.01% | 1130 |
|
|
2021
Q3 | $9.67M | Sell |
12,967
-591
| -4% | -$443K | 0.01% | 1117 |
|
|
2021
Q2 | $8.73M | Sell |
13,558
-4,152
| -23% | -$2.53M | 0.01% | 1164 |
|
|
2021
Q1 | $10.1M | Sell |
17,710
-12,558
| -41% | -$7.44M | 0.01% | 1139 |
|
|
2020
Q4 | $17.6M | Sell |
30,268
-791
| -3% | -$450K | 0.02% | 920 |
|
|
2020
Q3 | $16M | Buy |
31,059
+17,248
| +125% | +$8.74M | 0.02% | 894 |
|
|
2020
Q2 | $6.24M | Sell |
13,811
-7,006
| -34% | -$3.09M | 0.01% | 1123 |
|
|
2020
Q1 | $7.3M | Buy |
20,817
+2,438
| +13% | +$896K | 0.01% | 980 |
|
|
2019
Q4 | $6.8M | Sell |
18,379
-1,152
| -6% | -$406K | 0.01% | 1115 |
|
|
2019
Q3 | $6.5M | Buy |
19,531
+11,676
| +149% | +$3.81M | 0.01% | 1109 |
|
|
2019
Q2 | $2.46M | Buy |
+7,855
| New | +$2.35M | 0.01% | 1088 |
|
|
2019
Q1 | – | Sell |
-11,385
| Closed | -$2.64M | – | 1786 |
|
|
2018
Q4 | $2.64M | Sell |
11,385
-53
| -0.5% | -$14.2K | 0.01% | 975 |
|
|
2018
Q3 | $3.58M | Buy |
11,438
+3,195
| +39% | +$992K | 0.01% | 967 |
|
|
2018
Q2 | $2.38M | Buy |
8,243
+937
| +13% | +$259K | 0.01% | 1041 |
|
|
2018
Q1 | $1.83M | Buy |
+7,306
| New | +$1.86M | ﹤0.01% | 1091 |
|
|
2017
Q1 | – | Sell |
-7,445
| Closed | -$1.36M | – | 1807 |
|
|
2016
Q4 | $1.36M | Buy |
7,445
+859
| +13% | +$146K | ﹤0.01% | 1021 |
|
|
2016
Q3 | $1.08M | Buy |
+6,586
| New | +$1,000K | ﹤0.01% | 998 |
|
Other funds holding BIO
AI
Victory Capital Management's BIO Position: Q2 2026 in Review
Victory Capital Management increased its Bio-Rad Laboratories Class A (BIO) stake by 555% in Q2 2026, buying an estimated $29.4M and bringing the position to 122,126 shares worth $35.9M. The position accounts for 0.02% of the portfolio, ranked #713.
Victory Capital Management first reported a position in BIO in Q3 2016 and has held it in 35 quarters since. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- Victory Capital Management held 122,126 shares of Bio-Rad Laboratories Class A worth $35.9M as of Q2 2026.
- Victory Capital Management bought 103,487 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $29.4M.
- Bio-Rad Laboratories Class A made up 0.02% of Victory Capital Management's portfolio in Q2 2026, its #713 holding.
- Victory Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2016 and has held it in 35 quarters since.
- 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.